SMA-PET in Biochemically Recurrent Prostate Cancer: A Paradigm Shift
Gustavo Viani, Professor of Radiation Oncology at Ribeirão Preto Medical School, shared a recent article by Adrien Holzgreve on X:
“PSMA-PET in Biochemically Recurrent Prostate Cancer: A Paradigm Shift.
Recent findings reveal that PSMA-PET/CT detects M1 metastatic disease in 46% of previously classified as non-metastatic by conventional imaging.
This study sheds light on the limitations of traditional staging in high-risk, hormone-sensitive prostate cancer.
Key Findings:
- 84% PSMA-PET: Across with biochemical recurrence.
- 46% detected M1 disease: A substantial rate of under-staged metastases.
- Polymetastatic disease (>5 lesions): Found in 24% of cases.
Implications: Conventional imaging underestimates disease burden, potentially altering treatment plans. PSMA-PET offers accuracy for staging and risk stratification, guiding interventions like MDT and systemic treatment.”
Authors: Adrien Holzgreve, Wesley R. Armstrong, Kevyn J. Clark, Matthias R. Benz, Clayton P. Smith, Loïc Djaileb, Andrei Gafita, Pan Thin, Nicholas G. Nickols, Amar U. Kishan, Matthew B. Rettig, Robert E. Reiter, Johannes Czernin and Jeremie Calais.
Gustavo Viani, MD is an Associate Professor in the Department of Medical Imaging, Hematology, and Oncology at Hospital das Clínicas, Faculty of Medicine of Ribeirão Preto, University of São Paulo (FMRP-USP). Dr. Viani’s research focuses on radiation oncology, with expertise in brachytherapy, stereotactic radiosurgery, dose fractionation, radiation tolerance, and overall oncology practices.
More posts featuring Gustavo Viani.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023